Intrinsiqq
Moleculin Biotech Inc. logo

Moleculin Biotech Inc.

MBRX

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$8M
EPS$474.64
P/E0.02
P/FCF-0.30
EV/EBITDA-0.04
FCF Yield–
Div. Yield–
Net Debt/FCF0.3x
Moleculin Biotech Inc. intrinsic value
52-Week Range
$1.96$9.27

Profitability & Returns

Revenue (TTM)

$0.00

Net Income (TTM)

-$11M

▼ -28.8% YoY

Op. Margin

–

ROIC

-162.56%

▼ -54.6pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$27M

▲ +4.8% YoY

Op. Cash Flow (TTM)

-$27M

▲ +4.7% YoY

Net Debt

-$7M

Net Cash Position

Cash & Equiv.

$7M

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with MBRX

CompareIntrinsic value
BFRIBiofrontera Inc.
$0.53-7.02%30
LIFDLftd Partners Inc.
$0.11+0.00%35
SILOSilo Pharma Inc.
$1.73-7.98%10
NWBONorthwest Biotherapeutics Inc.
$0.13-7.86%30
LSTALisata Therapeutics Inc.
$0.90-1.22%10
ENVBEnveric Biosciences Inc.
$1.35-4.26%21
BFRGBullfrog AI Holdings Inc.
$0.36-8.72%40
ELABPMGC Holdings Inc.
$1.14-10.24%20

Moleculin Biotech (MBRX) in three numbers

Quality score
20/100
Best check: net debt, -$7M. Weakest: return on capital, -162.6%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
0.02
Price to free cash flow -0.30.
Financials

Questions about Moleculin Biotech

Is Moleculin Biotech (MBRX) overvalued?

Moleculin Biotech trades at 0.02 times earnings. Intrinsiqq's fair value calculator has no opening value for MBRX, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Is Moleculin Biotech a high-quality business?

Moleculin Biotech scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$7M, and its weakest is return on capital at -162.6%. The Quality tab shows every check against its target.

Does Moleculin Biotech (MBRX) pay a dividend?

No. Moleculin Biotech (MBRX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 6 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in MBRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing MBRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.